MR imaging of antigen-induced arthritis with a new, folate receptor-targeted contrast agent

Contrast Media and Molecular Imaging

Volumn 2, Issue 2, 2007, Pages 72-81

  Saborowski, Olaf ^a   Simon, Gerhard H ^a   Raatschen, Hans Juergen ^a   Wendland, Michael F ^a   Fu, Yanjun ^a   Henning, Tobias ^a   Baehner, Rick ^b   Corot, Claire ^c   Chen, Mei Hsiu ^a   Daldrup Link, Heike E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Laboratoire Guerbet   (France)

Author keywords

Arthritis; Folate receptors; Molecular imaging; MR imaging

Indexed keywords

CONTRAST MEDIUM; FOLATE RECEPTOR; GADOLINIUM CHELATE; GADOTERATE MEGLUMINE; P 1001; P 866; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC EMISSION SPECTROMETRY; BLOOD SAMPLING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HISTOPATHOLOGY; IMAGE DISPLAY; KNEE ARTHRITIS; MONARTHRITIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RELAXATION TIME; RHEUMATOID ARTHRITIS; SYNOVITIS;

ANIMALS; ANTIGENS; ARTHRITIS; CARRIER PROTEINS; CONTRAST MEDIA; DIAGNOSTIC IMAGING; EXTREMITIES; FEMALE; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MODELS, STATISTICAL; PERFUSION; PILOT PROJECTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE;

EID: 34249881075     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.128     Document Type: Article

References (55)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. New Engl. J. Med. 2001; 344: 907-916.
2. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR. Macrophages in rheumatoid arthritis. Arthritis Res. 2000; 2: 189-202.
3. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998; 41: 778-799.
4. Lethbridge-Cejku M, Schiller JS, Bernadel L. Summary health statistics for U. S. adults: National Health Interview Survey, 2002. Vital. Health. Statist. 2004; 10: 1-151.
5. Silman AJ, Pearson JE, Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002; 4(suppl. 3): S265-272.
6. Yamanishi Y, Firestein GS. Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum. Dis. Clin. N. Am. 2001; 27: 355-371.
7. Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum. 1996; 39: 115-124.
8. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, Meinders AE, Breedveld FC. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 1997; 40: 217-225.
9. Yanni G, Whelan A, Feighery C, Bresnihan B. Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann. Rheum. Dis. 1994; 53: 39-44.
10. Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara T, Nakamura T, Tsukano M, Ratnam M, Matsuyama T. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 1999; 42: 1609-1616.
11. Antony AC. Folate receptors. A. Rev. Nutr. 1996; 16: 501-521.
12. Ostergaard M, Hansen MS, Stoltenberg MB, Gideon P, Jensen KE, Klarlund M, Lorenzen I. [Magnetic resonance imaging as a marker of inflammation, destruction and prognosis in rheumatoid arthritis wrists]. Ugeskr. Laeger. 2000; 162: 4145-4149.
13. Schumacher HR, Pessler F, Chen LX. Diagnosing early rheumatoid arthritis (RA). What are the problems and opportunities? Clin. Exp. Rheumatol. 2003; 21: S15-19.
14. Tehranzadeh J, Ashikyan O, Dascalos J. Advanced imaging of early rheumatoid arthritis. Radiol. Clin. N. Am. 2004; 42: 89-107.
15. Turk MJ, Breur GJ, Widmer WR, Paulos CM, Xu LC, Grote LA, Low PS. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum. 2002; 46: 1947-1955.
16. Siegel BA, Dehdashti F, Mutch DG, Podoloff DA, Wendt R, Sutton GP, Burt RW, Ellis PR, Mathias CJ, Green MA, Gershenson DM. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J. Nucl. Med. 2003; 44: 700-707.
17. Herve-Somma CM, Sebag GH, Prieur AM, Bonnerot V, Lallemand DP. Juvenile rheumatoid arthritis of the knee: MR evaluation with Gd-DOTA. Radiology 1992; 182: 93-98.
18. Lutz AM, Seemayer C, Corot C, Gay RE, Goepfert K, Michel BA, Marincek B, Gay S, Weishaupt D. Detection of synovial macrophages in an experimental rabbit model of antigen-induced arthritis: ultrasmall superparamagnetic iron oxide-enhanced MR imaging. Radiology 2004; 233: 149-157.
19. Lutz AM, Weishaupt D, Persohn E, Goepfert K, Froehlich J, Sasse B, Gottschalk J, Marincek B, Kaim AH. Imaging of macrophages in soft-tissue infection in rats: relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics. Radiology 2005; 234: 765-775.
20. Poleksic L, Zdravkovic D, Jablanovic D, Watt I, Bacic G. Magnetic resonance imaging of bone destruction in rheumatoid arthritis: comparison with radiography. Skeletal Radiol. 1993; 22: 577-580.
21. McQueen FM. Magnetic resonance imaging in early inflammatory arthritis: what is its role? Rheumatology 2000; 39: 700-706.
22. Tehranzadeh J, Ashikyan O, Dascalos J. Magnetic resonance imaging in early detection of rheumatoid arthritis. Semin. Musculoskelet. Radiol. 2003; 7: 79-94.
23. Wiener EC, Konda S, Shadron A, Brechbiel M, Gansow O. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Invest. Radiol. 1997; 32: 748-754.
24. Corot C, Robert P, Lancelot E, Prigent P, Port M. Tumor imaging using a high relaxivity gadolinium chelate targeted to the folate receptor. In: Proceedings of the 13th Scientific Meeting of the International Society of Magnetic Resonance in Medicine, Miami, FL 2005; 2601.
25. Konda SD, Aref M, Wang S, Brechbiel M, Wiener EC. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. MAGMA 2001; 12: 104-113.
26. Beckmann N, Falk R, Zurbrugg S, Dawson J, Engelhardt P. Macrophage infiltration into the rat knee detected by MRI in a model of antigen-induced arthritis. Magn. Reson. Med. 2003; 49: 1047-1055.
27. Craciunescu CN, Brown EC, Mar MH, Albright CD, Nadeau MR, Zeisel SH. Folic acid deficiency during late gestation decreases progenitor cell proliferation and increases apoptosis in fetal mouse brain. J. Nutr 2004; 134: 162-166.
28. Kroft LJ, Doornbos J, van der Geest RJ, Benderbous S, de Roos A. Infarcted myocardium in pigs: MR imaging enhanced with slow-interstitial-diffusion gadolinium compound P760. Radiology 1999; 212: 467-473.
29. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-974.
30. Antony AC. The biological chemistry of folate receptors. Blood 1992; 79: 2807-2820.
31. Suh JR, Herbig AK, Stover PJ. New perspectives on folate catabolism. A. Rev. Nutr. 2001; 21: 255-282.
32. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994; 73: 2432-2443.
33. Konda SD, Aref M, Brechbiel M, Wiener EC. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress. Invest. Radiol. 2000; 35: 50-57.
34. Wiener EC, Brechbiel MW, Brothers H, Magin RL, Gansow OA, Tomalia DA, Lauterbur PC. Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn. Reson. Med. 1994; 31: 1-8.
35. Low PS, Antony AC. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv. Drug. Deliv. Rev. 2004; 56: 1055-1058.
36. Paulos CM, Turk MJ, Breur GJ, Low PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv. Drug. Deliv. Rev. 2004; 56: 1205-1217.
37. Chen WT, Mahmood U, Weissleder R, Tung CH. Arthritis imaging using a near-infrared fluorescence folate-targeted probe. Arthritis Res. Ther. 2005; 7: R310-317.
38. Hansch A, Frey O, Sauner D, Hilger I, Haas M, Malich A, Brauer R, Kaiser WA. In vivo imaging of experimental arthritis with near-infrared fluorescence. Arthritis Rheum. 2004; 50: 961-967.
39. McQueen FM, Crabbe J, Stewart N. Dynamic gadolinium-enhanced magnetic resonance imaging of the wrist in patients with rheumatoid arthritis: comment on the article by Cimmino et al. Arthritis Rheum. 2004; 50: 674-675. [Author reply 675-676].
40. McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, McLean L. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann. Rheum. Dis. 1998; 57: 350-356.
41. Ostergaard M, Klarlund M. Importance of timing of post-contrast MRI in rheumatoid arthritis: what happens during the first 60 minutes after IV gadolinium-DTPA? Ann. Rheum. Dis. 2001; 60: 1050-1054.
42. Rand T, Imhof H, Czerny C, Breitenseher M, Machold K, Turetschek K, Trattnig S. Discrimination between fluid, synovium, and cartilage in patients with rheumatoid arthritis: contrast enhanced Spin Echo versus non-contrast-enhanced fat-suppressed gradient echo MR imaging. Clin. Radiol. 1999; 54: 107-110.
43. Reiser MF, Bongartz GP, Erlemann R, Schneider M, Pauly T, Sittek H, Peters PE. Gadolinium-DTPA in rheumatoid arthritis and related diseases: first results with dynamic magnetic resonance imaging. Skeletal Radiol. 1989; 18: 591-597.
44. Choi H, Choi SR, Zhou R, Kung HF, Chen IW. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad. Radiol. 2004; 11: 996-1004.
45. Simon GH, von Vopelius-Feldt J, Wendland MF, Fu Y, Piontek G, Schlegel J, Chen MH, Daldrup-Link HE. MRI of arthritis: comparison of ultrasmall superparamagnetic iron oxide vs. Gd-DTPA. J. Magn. Reson. Imag. 2006; 23(5): 720-727.
46. Klareskog L. What can we learn about rheumatoid arthritis, from animal models? Springer Semin. Immunopathol. 1989; 11: 315-333.
47. Ke CY, Mathias CJ, Green MA. Folate-receptor-targeted radionuclide imaging agents. Adv. Drug. Deliv. Rev. 2004; 56: 1143-1160.
48. Ke CY, Mathias CJ, Green MA. The folate receptor as a molecular target for tumor-selective radionuclide delivery. Nucl. Med. Biol. 2003; 30: 811-817.
49. Konda SD, Wang S, Brechbiel M, Wiener EC. Biodistribution of a 153 Gd-folate dendrimer. generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts. Invest. Radiol. 2002; 37: 199-204.
50. Mathias CJ, Lewis MR, Reichert DE, Laforest R, Sharp TL, Lewis JS, Yang ZF, Waters DJ, Snyder PW, Low PS, Welch MJ, Green MA. Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nucl. Med. Biol. 2003; 30: 725-731.
51. Miotti S, Bagnoli M, Ottone F, Tomassetti A, Colnaghi MI, Canevari S. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines. J. Cell. Biochem. 1997; 65: 479-491.
52. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 2005; 338: 284-293.
53. Pinard MF, Jolivet J, Ratnam M, Kathmann I, Molthoff C, Westerhof R, Schornagel JH, Jansen G. Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate. Cancer Chemother. Pharmac. 1996; 38: 281-288.
54. Reddy JA, Xu LC, Parker N, Vetzel M, Leamon CP. Preclinical evaluation of (99 m)Tc-EC20 for imaging folate receptor-positive tumors. J. Nucl. Med. 2004; 45: 857-866.
55. Zhang L, Hou S, Mao S, Wei D, Song X, Lu Y. Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells. Int. J. Pharm. 2004; 287: 155-162.